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Hepatic encephalopathy (HE), the neuropsychiatric presentation of liver disease, is associated with high morbidity and mortality.
Reduction of plasma ammonia remains the central therapeutic strategy, but there is a need for newer novel therapies. We discuss
current evidence supporting the use of interventions for both the general management of chronic HE and that necessary for more
acute and advanced disease.
1.Introduction
There are a plethora of therapeutic approaches to targeting
varying severities of hepatic encephalopathy (HE), the neu-
ropsychiatric presentations of liver disease. There is a need
for newer therapies for patients with advanced HE and wors-
ening acute liver injury. Reduction of plasma ammonia re-
mains the central strategy although novel strategies may be
beneﬁcial. We discuss current evidence supporting the use of
therapeutic interventions for both the general management
of chronic HE and that necessary for more acute and ad-
vanced disease.
2. GeneralManagement of Chronic
Encephalopathy (Table 1)
2.1. Ammonia-Lowering Strategies
2.1.1. Dietary Protein Supplementation. Patients with cirrho-
sisoftenhaveapoornutritionalreserveduetoanorexia,poor
diet, malabsorption, and altered metabolic state. Hospital-
ized patients are often hypermetabolic and hypercatabolic,
worsened by complications such as gastrointestinal bleeding,
continued anorexia, and fasting for tests. Yet dietary protein
has the potential to drive further ammoniagenesis, and so
previously dietary protein restriction was common practice.
However, protein restriction is no longer advocated as does
not improve HE and may be harmful [1]. In fact high-
protein diets are well tolerated in cirrhotic patients [2], with
consensus supporting the need for normal or high dietary
protein (1–1.5g/kg protein and 25–40kcal/kg per day) [2,3].
Rare exceptions arise occasionally with inborn errors of
metabolism or acute liver failure (ALF) patients intubated
for grade 3-4HE associated with high circulating ammonia
whenproteinrestrictionwithmaintainedcalorieintake(e.g.,
dextrose infusion) is necessary.
2.1.2. Branched-Chain Amino Acids (BCAAs). BCAAs are
chieﬂy derived from dairy products and vegetables and
accountfor25%oftotaldietaryprotein.Theyareagoodsub-
strate for protein synthesis, both conserving and restoring
muscle mass in advanced liver disease. In cirrhosis, poor
dietary intake leads to a deﬁciency of BCAA and resultant
accumulation of aromatic amino acids, both worsening
protein-energy deﬁcits and glutaminergic neurotransmis-
sion (increased false neurotransmitter precursors). In “high
protein diet” intolerant and severely malnourished patients,
BCAA supplements may be useful to provide the necessary
nitrogen intake without a decline in mental state, with veg-
etable proteins likely to be better tolerated due to their
higher BCAA content. As BCAAs are under the inﬂuence of
circulating insulin, the insulin resistance state of cirrhosis
may limit there nutritional beneﬁt unless systemic insulin
replacement is implemented. However, a number of meta-
analyses have failed to ﬁnd consensus on the use of BCAAs in
cirrhosis from a wealth of conﬂicting data [4, 5].
In most cirrhotic patients, a modiﬁed eating pattern,
based on several meals and a late evening snack, is adequate
[4, 6].2 International Journal of Hepatology
Table 1: Treatment stratagems used in HE.
HE grade: I-II
General management
Hyperammonemia
Dietary protein supplementation
Purgatives
(i) Nonabsorbable disaccharides
(ii) Enemas
Non-absorbable antibiotics
Modulation of interorgan ammonia
(i) L-ornithine, L-aspartate (LOLA)
(ii) Sodium benzoate
(iii) Phenylacetate
Others
(i) Flumazenil “Bromocriptine” acarbose
Emerging therapies
(i) Probiotics
HE grade: III-IV
C e r e b r a le d e m a&e l e v a t e dI C P
General
(i) Ventilate
(ii) Sedate (e.g., Propofol)
Speciﬁc
(i) Antimicrobials
(ii) Hypertonic saline
(iii) Mannitol
(iv) Dexamethasone
(v) Induced hypothermia
(vi) Thiopentone
(vii) Indomethacin
(viii) Antiepileptic drugs (AED’S)
(ix) N-acetylcysteine (NAC)
Transplantation
Orthotopic liver transplant (OLT)
Partial hepatectomy
Liver assist devices
2.1.3.GlycaemicControl. Disturbedglycaemicandlipidcon-
trol is common in progressive liver disease and only wors-
ened by the stress response in critically unwell patients.
Therefore, once feeding has commenced, tight glycaemic
control using insulin may be necessary to reduce oxidative
stress (which triggers insulin resistance), limit mitochondrial
liver damage, and improve endothelial activation (e.g., NO
production), which will improve blood ﬂow, limiting tissue
injury, and improve outcome [7, 8].
2.1.4. Vitamins and Nutrients. Cirrhosis also leads to deﬁ-
ciencies of lipid-soluble vitamins, minerals, and micronutri-
ents. For example, Zinc is a cofactor in the urea cycle [9]a n d
also found in vesicles of predominately glutamatergic presy-
naptic terminals thereby having a role in neurotransmission
[10]. Zinc supplementation (600mg/day) has been studied
without obvious beneﬁt though replacement should be
considered if the patient is deﬁcient [11]. Autopsy specimens
from patients with hepatic coma and pallidal MR images
of patients with HE suggest that manganese deposition in
the basal ganglia may be a factor [12, 13]. However, as with
earlier studies evaluating the role of gut bacterial products
like mercaptans, phenols and medium- and short-chain
fatty acids [14], there has been little cumulative evidence to
support targeted treatment strategies.
3. Probiotics
Most of the ammonia produced by the gut is from the
deamination of dietary amino acids by bacteria, with a small
contribution from the urea produced by urease-positive bac-
teria. In the critically ill and malnourished patient, levels of
the predominant defensive bacteria strains (Biﬁdobacterium
and Lactobacillus) decline. Antibiotics may further lead to
ammonia-producing bacteria ameliorating hyperammon-
aemia. Probiotics are living nonpathogenic microorganisms
utilized as food ingredients that may have a role in the treat-
ment of HE. Probiotics are thought to exert an eﬀect in HE
by reducing intestinal ammonia production by enterocyte
glutaminase and reduce bacterial translocation, modulate
proinﬂammatory responses, and modulate gut permeability
[15]. Furthermore, probiotics bypass the small bowel and
get fermented by colonic bacteria to form lactic, acetic,
and butyric acids, and gas (mainly hydrogen); any resultant
intestinalhurrymayincreasetheexpulsionofammoniagenic
bacteria. In randomized placebo controlled trials [16],
probiotics have been shown to reduce gut ammonia pro-
duction and inﬂammation [16, 17]. It is worth noting that
fermentable ﬁbres alone were also beneﬁcial in that study.
This is not unexpected as the common eﬀect of probiotics,
aside from a decline of substrate for other bacteria [18]a n d
reduced translocation, is the fermentation of nonabsorbed
sugars (e.g., mono-, di- and oligosaccharides). This fer-
mentation of sugars leads to the production of diﬀerential
amounts of lactic acid, ethanol, and CO2 to modulate intes-
tinal acidity and gas production.
4.Purgatives
A purgative is an agent which cleanses the bowel by increas-
ing the evacuation of luminal contents. This is beneﬁcial in
HE as it allows for reduced intestinal ammonia production
and despite limited evidence from randomized controlled
trials remain the most widely used therapy for HE.
4.1. Nonabsorbable Disaccharides. It is unclear how non-ab-
sorbable disaccharides exert a beneﬁcial eﬀect. There have
been many proposed mechanisms (1) enhanced growth of
nonurease-producing bacteria [19], (2) catharsis secondary
to bowel acidiﬁcation reducing ammonia absorption [20,
21], (3) proliferation of healthy bacteria by providing addi-
tional carbohydrate and thus nitrogen (even as ammonia)
into protein, and/or (4) providing carbon and energy and so
spare bacterial ammonia metabolism [22]. More speciﬁcally,
lactulose(asugar)passesthroughthesmallbowelcompletely
undigested (unlike glucose, sucrose, and lactose, which areInternational Journal of Hepatology 3
easily fermented in the small bowel). Once in the colon,
lactulose is fermented by anaerobic bacteria, especially
Bacteroidesspp.Fermentation oflactulosebycolonicbacteria
yields important weak acids (lactic, acetic & butyric) and
gases (e.g., hydrogen). This leads to the acidiﬁcation of
ammonia into ammonium which is poorly absorbed. How-
ever, physiologically a total daily dose of 10–20g is small
compared to 500–1000g faeces/day, such that the impact on
acidity/reduced faecal pH on the faecal ﬂora is likely to be
limited. This is supported by the failure of mannitol and
sorbitol, which both cause low pH, to improve HE [23]. The
production of colonic hydrogen may be more important as
only 7g of lactulose produces 1 Litre of hydrogen that could
induce intestinal hurry and shift massive amounts of colonic
bacteria [24]. However, it may be the provision of energy in
preference to ammonia that accounts for the beneﬁt of non-
absorbable disaccharides.
A comprehensive meta-analysis of non-absorbable disac-
charides has suggested that current data from randomised
clinical trials do not support its routine use in clinical prac-
tice [25] though newer clinical studies suggest beneﬁt with
lactulose conferring improved neuropsychometric and qual-
ity of life scores [26], which lends weight to the overwhelm-
ing amount of anecdotal evidence that disaccharides are
beneﬁcial. It is likely that the impact of other therapies ini-
tiated at the same time often confounds any beneﬁt on HE
severity by the established ammonia-lowering eﬀect of non-
absorbable disaccharides.
Compliance,adverseeﬀects,clinicalsafely,andcosteﬀec-
tiveness are necessary concerns. It is often overlooked that
aggressive use of lactulose causes signiﬁcant gaseous disten-
sion, discomfort, and diarrhoea which may lead to poor
compliance. Furthermore, frank dehydration, prerenal urae-
mia, hyponatraemia, or aspiration of lactulose can occur.
Therefore, although non-absorbable disaccharides are rel-
atively cheap, their cost eﬀectiveness should be balanced
against clinical outcomes.
4.2. Other Purgatives. Enemas are beneﬁcial as a means of
expelling ammonia-producing gut ﬂora by both cleansing
and colonic acidiﬁcation [27] but are no better than oral
purgatives like lactulose. Therefore, if bowel motions can be
maintained at ≥2/day, then enemas may not oﬀer any addi-
tional beneﬁt.
5. Nonabsorbable Antibiotics
The contribution of intestinal urease-positive bacteria to gut
ammonia production is mainly in the colon rather than
gastric mucosa (e.g., Helicobacter pylori), due to their num-
ber and more alkaline colonic pH which favours enhanced
ammonia diﬀusion, such that Helicobacter pylori eradica-
tion has no therapeutic beneﬁt [28]. Oral, non-absorbable,
synthetic antibacterial agents such as Neomycin and Rifax-
imin have been used to inhibit the growth or kill suscep-
tible ammoniagenic bacterial species, showing comparable
eﬃcacy to lactulose [29]. Rifaximin is a synthetic antibiotic
related to rifamycin, with wide antibacterial activity against
bothaerobicandanaerobicgram-negativeandgram-positive
bacteria. In random controlled studies Rifaximin is proven
eﬃcacious (maintaining remission and reducing hospital-
ization with HE even in patients already on lactulose), and
a superior safety proﬁle and thus preferred to neomycin
[30, 31], Although beneﬁcial, non-absorbable antibiotics are
often reserved for patients who fail to respond to non-ab-
sorbable disaccharides.
6.Modulatorsof InterorganAmmonia
Metabolism(Figure1)
The concept of manipulating endogenous biosynthetic path-
ways to eliminate nonurea waste nitrogen as a substitute for
defective urea synthesis is well established [32]. Despite ab-
normal urea-cycle functioning, reducing total body nitrogen
by promoting the synthesis of non-urea nitrogen-containing
metaboliteswithhighexcretionratesappearstobeofbeneﬁt.
6.1. Arginine Supplementation. L-arginine is an important
dietarysubstratefortheureacyclewhichallowsforammonia
detoxiﬁcation to urea (via arginase). L-arginine is a semi-
essential amino acid, as although metabolically produced, in
some disease states may require dietary supplementation. In
cases of the childhood urea cycle disorders (e.g., deﬁciency
of argininosuccinate synthetase (AS) and argininosuccinase
(AL)), dietary restriction of L-arginine triggers the rapid de-
velopment (15–68hours) of symptomatic hyperammon-
aemia (e.g., vomiting, lethargy, or irritability) [33]. In these
disorders, there is a signiﬁcant reduction in urea production,
with nitrogen instead accumulating as mainly glutamine,
ammonium, and to a limited extent alanine and glutamate.
In AS and AL deﬁciency, the provision of additional dietary
L-arginine promotes the synthesis of citrulline and argini-
nosuccinate, allowing for the urinary excretion of nitrogen.
In ALF, systemic hypotension and cerebral oedema may
be associated with increased plasma nitric oxide (NO) levels.
L-arginine is the rate-limiting substrate for NO production
but is deﬁcient in ALF due possibly to increased arginase
activity in the liver which converts it to urea and ornithine.
There have been no clinical studies evaluating a role for
L-arginine supplementation in HE, though animal studies
suggest that correcting L-arginine deﬁciency may alter portal
hypertension and cerebral oedema via arginase-dependent
reduction in hyperammonaemia and/or NO-dependent
mechanism(s).
6.2. Phenylbutyrate. Phenylbutyrate (converted to phenylac-
etate in vivo) is an established therapy for hyperammon-
aemia associated with urea cycle disorders [34], which are
characterized by elevated glutamine levels. This excess can
be mopped up by phenylacetate, which covalently combines
with circulating glutamine to form renally excreted pheny-
lacetylglutamine, removing glutamine as a substrate for
ammoniagenesis. So far phenylbutyrate has proved ineﬀec-
tive in the treatment of HE associated with liver failure,
probably because a high glutamate state, a prerequisite for
phenylacetate to work, is absent in liver failure.4 International Journal of Hepatology
Figure 1: Therapies manipulating interorgan ammonia and amino acid metabolism. In liver failure, the relative activities of cellular
glutamine syntheses (GS) and phosphate-activated glutaminase (PAG) in diﬀerent organs inﬂuence interorgan ammonia and amino acid
metabolism. With a loss of hepatic urea cycle capacity, hyperammonaemia is predominately due to worsening intestinal and renal ammonia
eﬄux, with skeletal muscle having the potential to increase its ability to detoxify ammonia. Though the brain also detoxiﬁes ammonia, this is
counterproductiveasresultantastrocyteglutamineaccumulationinducesbrainswelling.Thisschematichighlightsnotonlycurrentstandard
therapies for hyperammonaemia which principally act on individual organs (e.g., purgatives targeting intestinal ammonia production), but
also newer interventions targeting multiple organs (e.g., LOLA and OP).
6.3. Sodium Benzoate. Similarly sodium benzoate increases
the renal excretion of ammonia but as hippuric acid (hip-
purate), the glycine conjugate of benzoic acid [32]. Sodium
benzoate also improves the encephalopathy with inborn
errors of metabolism [35] and is as eﬀective as lactulose in
the treatment of acute portosystemic HE [36].
6.4. Combined Intravenous Sodium Phenylbutyrate and Ben-
zoate (Ammonul, Ucyclyd Pharma). In urea-cycle disorders,
combination therapy results in a 79% reduction in plasma
ammonia, and 84–98% improved survival with late onset
disease, though poor in neonates and high peak ammonia
values [37]. If untreated, only 16% of neonates survive, com-
pared to 72% with late onset disease [38]. However, as the
N-acyltransferasesthat conjugateglutamine to phenylacetate
and glycine to benzoate are located in the liver and kidney,
the severe hepatotoxicity of ALF may eventually lead to
response failure, especially with the saturation of enzyme
capacity (e.g., phenylacetate to PAG) [39, 40].
6.5. L-Ornithine L-Aspartate (LOLA). LOLA provides L-or-
nithine and L-aspartate as substrates for glutamate produc-
tion in muscle leading to a reduction in circulating ammonia
and in models of liver failure further suggest that LOLA
reduces brain oedema of advanced HE [41]. In a double-
blind randomized control study of cirrhotics with mild HE,
one week of LOLA reduced ammonia and improved mental
function [42]. A cross-over study showed that 20–40g/day of
infused LOLA ameliorated postprandial increases in ammo-
nia following oral protein loading [43]. However, at higher
doses, this study increased plasma glutamate, unchanged
glutamine, and increasedurea production[43]contradicting
the muscle ammonia detoxiﬁcation hypothesis. Further-
more, 40g dosing induced hyperglycaemia and hyperinsuli-
naemia [43]. As yet, there are no studies in patients with
ALF, and its use in ALF is currently not recommended.
Critically, there are concerns that the ammonia-lowering
eﬀects of LOLA may only be transient, due to rebound
hyperammonaemia on stopping LOLA [44], as a signiﬁcant
rise in glutamine levels eventually becomes a source for
ammoniagenesis by the kidney and intestines (through glu-
taminase) [45]. Additionally, aspartate is unlikely to oﬀer
added beneﬁt as in animal models it failed to reduce
ammonia [46].
6.6. L-Ornithine Phenylacetate (OP). OP is a novel therapy
targeting interorgan ammonia and amino acid metabolism
[44]. OP reduces toxic levels of ammonia by ornithine acting
as a substrate for glutamine synthesis from ammonia in
skeletal muscle. This combination unlike other therapies
targeting interorgan ammonia metabolism (e.g., LOLA), by
stopping the recycling of ammonia (trapped as ornithine-
glutamine) via phenylacetate excreting the ornithine-related
glutamine as phenylacetylglutamine in the kidneys. It has
been shown to correct the hyperammonemic state in animal
modelsofcirrhosis[47]andALF[48],limitingbrainoedema
and rises in ICP. Clinical studies are currently underway.
7.Others
7.1. Acarbose. The hypoglycaemic agent acarbose which
stimulates gut motility, through the inhibition of intestinal
glucose absorption by promoting intestinal saccharolyticInternational Journal of Hepatology 5
Table 2: Precipitating factors in hepatic encephalopathy.
Precipitating factors in HE
Constipation
Dehydration
Gastrointestinal bleeding
Infection
Excessive dietary protein
Hypokalaemia
Hypoglycaemia
Hypothyroidism
Hypoxia
Metabolic alkalosis
Anaemia
Azotaemia/uraemia
Medications (narcotics, sedatives, etc.)
Hepatoma
TIPS, surgical shunt
Vascular occlusion
bacterial ﬂora in preference to proteolytic ﬂora, thereby
reducing substrate for ammonia production. In a cross-over
randomizedtrialofcirrhoticpatientswithlow-gradeHEand
type-2 diabetes mellitus, 8 weeks of acarbose (100mgs TDS)
signiﬁcantly decreased ammonia blood levels, and intellec-
tual function, aside from decreasing fasting and postprandial
glucose, and reducing glycosylated haemoglobin levels [49].
However, acarbose is unlikely to be an option except in those
with coexistent type-2 diabetes mellitus.
7.2. Bromocriptine. Bromocriptine, a dopamine agonist, has
been used with limited success for disturbances in dopamin-
ergic neurotransmission associated with chronic intractable
HE [50, 51], but such studies failed to show a clear beneﬁt
over standard therapy [49]. Furthermore, in cirrhotic pa-
tients with ascites, it can induce hyponatraemia [52]. How-
ever,thereisanecdotalevidencetosuggestabeneﬁtinasmall
number of cirrhotic patients with low-grade encephalopathy
andbasalgangliainjurywithassociateddopaminedeﬁciency.
8. Correctionof PrecipitatingFactors
(Table 2)
Worsening encephalopathy is often precipitated by a number
of factors which can be anticipated and promptly corrected.
Though HE may be triggered by uncommon events, it is
important to outline the management of the more common
precipitants.
8.1. Constipation. Enemas are beneﬁcial as a mean of expel-
ling ammonia producing gut ﬂora either due by cleansing
or colonic acidiﬁcation [27]. However, there is only limited
evidence to show a beneﬁt over the use of oral purgatives like
lactulose. Therefore, if bowel motions can be maintained at
≥2/day, enemas are only used as an adjunct to the primarily
used non-absorbable disaccharides.
8.2. Infections. bacterial infections predispose to variceal
bleeding in cirrhotic patients. A meta-analysis of antibiotic
use in variceal bleeding reported a 30% decrease in rate
of infection and 9% improvement in short-term survival
[53, 54]. Septic encephalopathy may also confound or mimic
HE.
8.3. Gastrointestinal Bleeding. Due to the high-protein con-
tent of blood and thus nitrogenous load, there is increased
intestinal ammonia production. This ammoniagenic blood
meal and precipitation of HE are potentially related to an
absence of the branched-chain amino acid isoleucine which
protects the inhibitory eﬀect of ammonia on the TCA cycle
in neuronal cells.
8.4. Portosystemic Shunts. Persistent shunts may account for
worsening HE poorly responsive to standard oral therapies
and may be best treated by shunt closure.
8.5. TIPSS Insertion. T h ec r e a t i o no fap o r t o s y s t e m i cs h u n t
(usedtostabilizepatientswithuncontrolledvaricealbleeding
or intractable ascites) may induce HE (especially within
the ﬁrst few months). Prophylaxis against encephalopathy
with Lactitol (60g/day) or Rifaximin (1200mg/day) is not
proventobeeﬀectiveduringtheﬁrstmonthafterTIPSS[55].
Therefore,carefulselectionofpatientsforaTIPSSorsurgical
shunt is necessary.
9. Acute Severe HE: IntracranialHypertension
andC e r eb ralO ed e m a(Table 1)
ALF is characterised by rapid onset HE with cerebral oedema
and intracranial hypertension and progression to coma
stages, independently associated with a 30% mortality [56].
Earlyventilation, intensivecareunitadmissionandjudicious
use of available therapies have led to a signiﬁcant decline in
deaths as a result of cerebral oedema. Aiding liver recovery
by prompt and speciﬁc treatment of the cause of acute liver
injury, treating precipitating factors such as dehydration,
electrolyteand acid-base imbalance, [57], infection [58],and
ameliorating hyperammonaemia remain at the forefront of
therapy. The following therapeutic strategies are utilized in
the management of severe HE requiring ventilation.
10. General
Early airway maintenance is necessary to protect the airway
and prevent high carbon dioxide tension and hypoxia
which can result in cerebral hyperaemia [59]. Sedation and
mechanical ventilation is also essential to safely manage
agitation. Once intubated, the head should be elevated by
10–20◦ with minimal intervention and care when moving
patients and optimize intracranial pressure (ICP) without
compromising the cerebral perfusion pressure [60, 61]. Air-
way protection will also reduce the likelihood of aspiration,
pneumonia, defective gas exchange, and infection. Sedative
requirements (e.g., fentanyl, midazolam, or propofol) are
low with worsening severity of HE but are likely to increase
with recovery. Propofol is a useful sedative because it will6 International Journal of Hepatology
reduce ICP, and because of its nonhepatic metabolism will
not accumulate. It may, however, induce hypotension [62].
10.1. Circulatory Support and Fluid Management. ALF is a
hyperdynamic state with high cardiac output, low mean
arterial pressure, and low systemic vascular resistance [63].
Generalized vasodilatation, which produces profound acti-
vation of the neurohormonal system, culminates in vaso-
constriction of regional vascular beds [64]. Mean arterial
pressure should be maintained at a level to keep the cerebral
perfusionpressurebetween50and65mmHg[65].Theonset
of multiorgan failure often necessitates the use of inotropes.
Circulatoryfailureoftenbecomesrefractorytoinotropesand
up to 70% of patients die [66]. A routine short synacthen
test on admission to guide the use of steroids is important as
adrenal insuﬃciency is a common complication of ALF [67].
10.2. Renal Support. Renal dysfunction is common due to
either prerenal, hepatorenal, or nephrotoxic (e.g., acetam-
inophen) injury [68]. This frequently requires renal replace-
ment [66] with continuous (compared to intermittent) hae-
moﬁltration [69]. This avoids rapid water shifts seen with
intermittent therapy [70], providing greater haemodynamic
stability and improved cerebral perfusion pressure [69, 71].
Furthermore, due to impaired hepatic lactate metabolism,
lactate-free dialysates are preferred [72].
10.3. Electrolyte Imbalance. Electrolyte imbalance should be
corrected aggressively. Hyponatraemia ≤125mmol/L may
precipitate cerebral oedema and is a contraindication for
orthotopic livertransplant (OLT)[73,74].Inducedhyperna-
traemiahasbeenshowntoimproveICPandreduceinotropic
requirements in traumatic brain injury and ALF [75].
10.4. Antimicrobial Agents. The incidence of sepsis in ALF
is a signiﬁcant factor in mortality and a contraindication
to transplantation. Around 75% develop bacterial and 30%
fungal infections [76, 77]. The administration of broad-
spectrum antibiotics/antifungal therapy should be initiated
at the ﬁrst sign of infection, with focused treatment once the
organism is identiﬁed. Despite the absence of randomized
control trials of prophylactic systemic antimicrobials in ALF,
their use is widespread [78, 79].
10.5. Glycaemic Control. Both hyper- and hypoglycaemia
needrapidcorrectionastheymayworsenbrainoedema.The
role of tight glycaemic control in ALF has not been ascer-
tained but must be instituted with caution because of the
tendency for the development of hypoglycaemia.
11.Speciﬁc
11.1. Mannitol. Mannitol (an osmotic diuretic) increases
brain capillary osmolality, drawing water from the brain
tissueintothecapillaries,andhasbeenshowntosigniﬁcantly
reduce the extent of cerebral oedema and improve survival
[80,81]. Bolus doses of 20% mannitol at 1g/kg are preferred.
Plasma osmolality should be kept <320Osm/L, as mannitol
is less eﬀective with increasing osmolality. If patient is
oliguric,mannitolmayaccumulateandcanonlybeusedwith
concomitant haemoﬁltration.
11.2. Dexamethasone. In ALF, reducing inﬂammation
(whether systemic or local) by utilizing the anti-inﬂam-
matory eﬀects of steroids may improve cerebral haemo-
dynamics and prevent/treat intracranial hypertension [79,
82, 83]. However, trials using dexamethasone in advanced
ALF have shown little eﬀect on the frequency of cerebral
oedema or survival [80].
11.3. Mild Hypothermia. In models of ALF, induced hypo-
thermia signiﬁcantly reduces brain water, duration of en-
cephalopathy,andimprovedoutcome[84–86].Usingcooling
blankets to induce moderate hypothermia (target core temp.
32–33◦C) can lead to a reduction in ICP, even in patients
unresponsive to mannitol and/or ultraﬁltration [87, 88].
Hypothermia also signiﬁcantly improves cardiovascular
haemodynamics with reduced noradrenaline requirements
[88], likely related to a reduction in arterial ammonia and
alsobrainammoniaextractionandﬂux[87,89].Asyet,there
is no data from randomized control trials on the use of
hypothermiainALFbutisworthconsideringinpatientswith
uncontrolled intracranial hypertension.
11.4. Thiopental Sodium. By inducing cerebral vasocon-
striction through the inhibition of nitric oxide synthetase,
intermittent bolus injections of thiopental (1.5–3.5mg/kg)
reduce elevations of ICP [90]. However, its use is limited to
intractable increases in ICP unresponsive to other therapies.
Because of profound negative eﬀects on systemic haemody-
namics, its use is limited.
11.5. Indomethacin. Nonsteroidal anti-inﬂammatory
(NSAIDS) may modulate brain function [91] (with pos-
sible eﬀects on cognitive function via modulation of the
glutamate-nitric oxide-cyclic GMP pathway [92]). Indo-
methacin (0.5mg/kg), a nonselective cyclooxygenase inhibi-
tor [93], can reduce ICP and cerebral oedema independent
of a change in cerebral blood ﬂow [94]. However, its use is
limited by nephrotoxicity, platelet dysfunction, and risk of
gastrointestinal bleeding. Poor brain penetration of NSAIDs
at therapeutic levels requires high doses which increases the
risk of toxicity [92, 95].
11.6. Antiepileptic Drugs (AED’s). In some ALF patients with
grade 3-4HE, subclinical seizures occur, and the use of phe-
nytoin was shown to signiﬁcantly reduced seizure frequency
and the development of increased ICP [96].
11.7. N-Acetylcysteine (NAC). In a case of acetaminophen
overdose, NAC must be continued irrespective of the time
between the overdose and presentation and acetaminophen
level as it can prevent the progression of ALF and reduces
mortality especially in those who progress to grade III–IV
HE [97]. There is less convincing evidence for NAC in
nonacetaminophen overdose[98,99].Innonacetaminophen
ALF, NAC may improve survival by its eﬀects on cardiac
output, oxygen extraction and consumption, and due to itsInternational Journal of Hepatology 7
antioxidant eﬀects that ameliorate the signiﬁcant oxidative
stresses that occur with liver failure.
11.8. Flumazenil. In a large placebo controlled trial focusing
on intensive care patients with advanced HE (grade III-IV),
the short-acting benzodiazepine-receptor antagonist ﬂuma-
zenil was shown to rapidly improve the neurological score
in 15% and electroencephalogram (EEG) ﬁndings in 30%
of patients within minutes of its administration [100]. How-
ever, ﬂumazenil does not lead to any lasting eﬀect or correct
HE, unless coadministered with a long-acting therapy [101],
a n da ss u c hi sn o tr e c o m m e n d e d .
12. LiverSupport andTransplantation
12.1.Transplantation. Transplantationoﬀersdeﬁnitiveinter-
vention for liver failure with a swift return to a normal men-
talstatethoughminimalHEmaypersistinafewduetosome
asyetunknownirreversiblecerebralchanges[102].Disparity
between donor organs and recipients has led to a plethora of
extracorporeal liver assist devices [103, 104] and even partial
hepatectomy [83, 105] to aid or supplant the failing liver.
12.2.ExtracorporealLiverAssistDevices. Suchdevicesmaybe
either “biological” (using either immortalised cultured hep-
atocytes or whole animal livers), or “nonbiological” (using
extracorporeal blood puriﬁcation to dialyse albumin-bound
hydrophobic substances), ultimately mimicking endogenous
excretory and synthetic liver function. The extracorporeal
devices under clinical evaluation include the following.
Molecular Adsorbent Recirculating System (MARS). It
providescounter-currenthaemodialysisagainstalbuminand
bicarbonate circuits.
Single-PassAlbuminDialysis(SPAD).Itprovidescounter -
current albumin dialysis against high-ﬂow blood in a ﬁbre
haemodiaﬁlter,whichunlikeMARSisdiscardedafterpassing
the ﬁlter. As it uses a standard renal dialysis device, continu-
ous venovenous haemodiaﬁltration is possible.
Prometheussystem.Itprovidesdirectalbuminadsorption
with high-ﬂux haemodialysis after selective ﬁltration of the
albumin fraction through a speciﬁc polysulfone ﬁlter.
All devices successfully remove protein-bound toxins but
have variable eﬀects on systemic (versus portal) haemo-
dynamics, and the potential to worsen coagulopathy. The
clinicalbeneﬁtofsuchdevicesisunclearbutmayatleastoﬀer
a bridge to either transplantation or liver recovery.
13. Conclusion
Ammonia-lowering therapy remains at the cornerstone of
standard medical care for HE, along with measures to treat
precipitating factors and speciﬁc interventions for the cere-
bral sequelae of advanced disease. Understanding interorgan
ammonia metabolism and the pathophysiological basis of
HE are most likely to lead to the development of new
therapeutic approaches [45] .H o w e v e r ,t h e r ei sal a c ko fc o n -
clusive evidence from clinical studies even for current best
practice [25, 106] and, therefore, a requirement for robust
randomized controlled trials to drive a more evidence-based
approach.
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